PURPOSE OF REVIEW: Systemic infections in premature and term infants cause significant morbidity and mortality in spite of appropriate antimicrobial therapy. Consequently, immunotherapy has emerged as a potential adjuvant therapeutic modality to reduce the incidence and mortality associated with neonatal sepsis. RECENT FINDINGS: The most recent findings during the review period include systematic reviews of previously published trials evaluating the use of intravenous immunoglobulin and colony-stimulating factors in neonatal sepsis. In addition, the most recent trials describing the use of antistaphylococcal antibodies, probiotics, glutamine supplementation, recombinant human protein C, and lactoferrin in the prevention and treatment of neonatal sepsis have been reviewed. SUMMARY: Immunotherapy used as an adjuvant for the prevention and treatment of neonatal sepsis holds promise. Clinical trials specifically designed toward the neonatal population and appropriately powered to detect treatment differences are necessary prior to universal recommendation of these therapies in the nursery.
PURPOSE OF REVIEW: Systemic infections in premature and term infants cause significant morbidity and mortality in spite of appropriate antimicrobial therapy. Consequently, immunotherapy has emerged as a potential adjuvant therapeutic modality to reduce the incidence and mortality associated with neonatal sepsis. RECENT FINDINGS: The most recent findings during the review period include systematic reviews of previously published trials evaluating the use of intravenous immunoglobulin and colony-stimulating factors in neonatal sepsis. In addition, the most recent trials describing the use of antistaphylococcal antibodies, probiotics, glutamine supplementation, recombinant humanprotein C, and lactoferrin in the prevention and treatment of neonatal sepsis have been reviewed. SUMMARY: Immunotherapy used as an adjuvant for the prevention and treatment of neonatal sepsis holds promise. Clinical trials specifically designed toward the neonatal population and appropriately powered to detect treatment differences are necessary prior to universal recommendation of these therapies in the nursery.
Authors: Barbara J Stoll; Nellie I Hansen; Rosemary D Higgins; Avroy A Fanaroff; Shahnaz Duara; Ronald Goldberg; Abbot Laptook; Michelle Walsh; William Oh; Ellen Hale Journal: Pediatr Infect Dis J Date: 2005-07 Impact factor: 2.129
Authors: Anemone van den Berg; Ruurd M van Elburg; T Teerlink; Harrie N Lafeber; Jos W R Twisk; Willem P F Fetter Journal: J Pediatr Gastroenterol Nutr Date: 2005-07 Impact factor: 2.839
Authors: D K Benjamin; R Schelonka; R White; H P Holley; E Bifano; J Cummings; K Adcock; D Kaufman; B Puppala; P Riedel; B Hall; J White; C M Cotton Journal: J Perinatol Date: 2006-05 Impact factor: 2.521
Authors: P Manzoni; M Mostert; M L Leonessa; C Priolo; D Farina; C Monetti; M A Latino; G Gomirato Journal: Clin Infect Dis Date: 2006-05-04 Impact factor: 9.079
Authors: Anemone van den Berg; Ruurd M van Elburg; Elisabeth A M Westerbeek; Jos W R Twisk; Willem P F Fetter Journal: Am J Clin Nutr Date: 2005-06 Impact factor: 7.045
Authors: Brenda B Poindexter; Richard A Ehrenkranz; Barbara J Stoll; Linda L Wright; W Kenneth Poole; William Oh; Charles R Bauer; Lu-Ann Papile; Jon E Tyson; Waldemar A Carlo; Abbot R Laptook; Vivek Narendran; David K Stevenson; Avroy A Fanaroff; Sheldon B Korones; Seetha Shankaran; Neil N Finer; James A Lemons Journal: Pediatrics Date: 2004-05 Impact factor: 7.124
Authors: A A Fanaroff; S B Korones; L L Wright; E C Wright; R L Poland; C B Bauer; J E Tyson; J B Philips; W Edwards; J F Lucey Journal: N Engl J Med Date: 1994-04-21 Impact factor: 91.245
Authors: Anna C Seale; Hannah Blencowe; Anita Zaidi; Hammad Ganatra; Sana Syed; Cyril Engmann; Charles R Newton; Stefania Vergnano; Barbara J Stoll; Simon N Cousens; Joy E Lawn Journal: Pediatr Res Date: 2013-12 Impact factor: 3.756